Perspective Therapeutics (CATX) Accounts Payables (2011 - 2026)

Perspective Therapeutics has disclosed Accounts Payables across 16 years of filings, most recently posting $29.4 million for Q2 2026.

• In Q2 2026, Accounts Payables rose 317.4% year-over-year to $29.4 million; the TTM figure through Jun 2026 stood at $29.4 million (up 317.4% YoY), while the FY2025 annual figure was $20.5 million, up 98.31% from the prior year.
• Accounts Payables came in at $29.4 million for Q2 2026 at Perspective Therapeutics, up from $26.5 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $29.4 million in Q2 2026 to a low of $769000.0 in Q1 2022.
• Average Accounts Payables over 5 years is $9.7 million, with a median of $6.5 million recorded in 2023.
• Year-over-year, Accounts Payables jumped 464.08% in 2024 and sank 39.72% in 2025.
• Over 5 years, Accounts Payables stood at $1.5 million in 2022, then jumped by 348.35% to $6.9 million in 2023, then soared by 49.7% to $10.3 million in 2024, then surged by 98.31% to $20.5 million in 2025, then jumped by 43.43% to $29.4 million in 2026.
• Per Business Quant data, the three most recent Accounts Payables figures were $29.4 million in Q2 2026, $26.5 million in Q1 2026, and $20.5 million in Q4 2025.